

# Francesco Tandoi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8696895/publications.pdf>

Version: 2024-02-01

77  
papers

1,096  
citations

489802

18  
h-index

511568

30  
g-index

78  
all docs

78  
docs citations

78  
times ranked

1774  
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of Graft Fibrosis, Inflammation, and Donor-specific Antibodies at Protocol Liver Biopsies in Pediatric Liver Transplant Patients: A Single-center Experience. <i>Transplantation</i> , 2022, 106, 85-95.	0.5	8
2	Impact of MELD 30-allocation policy on liver transplant outcomes in Italy. <i>Journal of Hepatology</i> , 2022, 76, 619-627.	1.8	8
3	Outcome of liver transplantation with grafts from brain-dead donors treated with dual hypothermic oxygenated machine perfusion, with particular reference to elderly donors. <i>American Journal of Transplantation</i> , 2022, 22, 1382-1395.	2.6	41
4	Liver Transplantation in Hepatitis B/Hepatitis D (Delta) Virus Coinfected Recipients. <i>Transplantation</i> , 2022, 106, 1935-1939.	0.5	7
5	Bacterial and Viral Infections in Liver Transplantation: New Insights from Clinical and Surgical Perspectives. <i>Biomedicines</i> , 2022, 10, 1561.	1.4	3
6	Carrying on with liver transplantation during the COVID-19 emergency: Report from piedmont region. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101512.	0.7	4
7	Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients. <i>Scientific Reports</i> , 2021, 11, 443.	1.6	6
8	The Clinical Role of Serum Epidermal Growth Factor Receptor 3 in Hepatitis C Virus-Infected Patients with Early Hepatocellular Carcinoma. <i>Biology</i> , 2021, 10, 215.	1.3	4
9	Combined liver kidney transplantation for primary hyperoxaluria type 1: Will there still be a future? Current transplantation strategies and monocentric experience. <i>Pediatric Transplantation</i> , 2021, 25, e14003.	0.5	3
10	Three-dimensional Printing in Pediatric Living Donor Liver Transplantation Planning. <i>Liver Transplantation</i> , 2021, 27, 1865-1866.	1.3	1
11	Liver transplantation from active COVID-19 donors: A lifesaving opportunity worth grasping?. <i>American Journal of Transplantation</i> , 2021, 21, 3919-3925.	2.6	56
12	The hepatitis D virus in Italy. A vanishing infection, not yet a vanished disease. <i>Journal of Advanced Research</i> , 2021, 33, 183-187.	4.4	16
13	Development of a Risk Prediction Model for Carbapenem-resistant <i>Enterobacteriaceae</i> Infection After Liver Transplantation: A Multinational Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e955-e966.	2.9	22
14	Monitoring Tacrolimus Concentrations in Whole Blood and Peripheral Blood Mononuclear Cells: Inter- and Intra-Patient Variability in a Cohort of Pediatric Patients. <i>Frontiers in Pharmacology</i> , 2021, 12, 750433.	1.6	4
15	Intrahepatic Administration of Human Liver Stem Cells in Infants with Inherited Neonatal-Onset Hyperammonemia: A Phase I Study. <i>Stem Cell Reviews and Reports</i> , 2020, 16, 186-197.	1.7	23
16	Prognostic Role of Serum Cytokeratin-19 Fragment (CYFRA 21-1) in Patients with Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 2776.	1.7	14
17	Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology. <i>Cancers</i> , 2020, 12, 3218.	1.7	27
18	Outcome of COVID-19 in liver transplant recipients: A preliminary report from Northwestern Italy. <i>Transplant Infectious Disease</i> , 2020, 22, e13353.	0.7	27

#	ARTICLE	IF	CITATIONS
19	Use of Dual Hypothermic Oxygenated Machine Perfusion to Recover Extended Criteria Pediatric Liver Grafts. <i>Liver Transplantation</i> , 2020, 26, 835-839.	1.3	10
20	â€œU-shapedâ€•mesoportal jump graft to manage portal vein thrombosis during liver transplantation: A case report. <i>International Journal of Surgery Case Reports</i> , 2020, 71, 73-77.	0.2	1
21	Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 96, 114985.	0.8	14
22	FRI-367-Pre-liver transplant profile of cardiovascular risk factors and its impact on early post-transplant outcome. <i>Journal of Hepatology</i> , 2019, 70, e556-e557.	1.8	2
23	Hypothermic Oxygenated Machine Perfusion of Liver Grafts from Brain-Dead Donors. <i>Scientific Reports</i> , 2019, 9, 9337.	1.6	81
24	THU-208-Characterization of a novel chemiluminescent enzyme immunoassay for the quantitation of antibodies to hepatitis B core antigen class IgG and correlation with intrahepatic HBV covalently-closed-circular DNA. <i>Journal of Hepatology</i> , 2019, 70, e254-e255.	1.8	1
25	Pre-liver transplant cardiovascular risk profile and correlation with early post-transplant cardiac events. <i>Digestive and Liver Disease</i> , 2019, 51, e52.	0.4	0
26	Combined liver and hematopoietic stem cell transplantation in patients with X-linked hyper-IgM syndrome. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1952-1956.e6.	1.5	10
27	Differential Intraoperative Effect of Liver Transplant in Different Inborn Errors of Metabolism. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2019, 69, 160-162.	0.9	6
28	Quantitation of anti-HBe antibodies in anti-HBc-positive liver donors. <i>Journal of Hepatology</i> , 2019, 70, 793-795.	1.8	4
29	Hereditary pancreatitis in Paediatrics: the causative role of p.Leu104Pro mutation of cationic trypsinogen gene also in young subjects. <i>Gut</i> , 2019, 68, 767-768.	6.1	3
30	Role of hepatitis B core-related antigen and antibodies to hepatitis B core antigen levels in the natural history of chronic HBV infection. <i>Digestive and Liver Disease</i> , 2018, 50, 12.	0.4	0
31	Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: A new tool to detect occult infection. <i>Journal of Hepatology</i> , 2018, 69, 301-307.	1.8	126
32	Successful Sequential Liver and Hematopoietic Stem Cell Transplantation in a Child With CD40 Ligand Deficiency and Cryptosporidium-Induced Liver Cirrhosis. <i>Transplantation</i> , 2018, 102, 823-828.	0.5	11
33	A simplified regimen of targeted antifungal prophylaxis in liver transplant recipients: A single-center experience. <i>Transplant Infectious Disease</i> , 2018, 20, e12859.	0.7	17
34	Transient elastography for non-invasive evaluation of post-transplant liver graft fibrosis in children. <i>Pediatric Transplantation</i> , 2018, 22, e13125.	0.5	27
35	Direct-acting antiviral therapy immediately after liver transplant in naïve or NS5A-relapser recipients. <i>Digestive and Liver Disease</i> , 2018, 50, 60.	0.4	0
36	Outcome of liver grafts procured from hepatitis C-positive donors in the era of direct-acting antiviral drugs: a preliminary single centre experience. <i>Journal of Hepatology</i> , 2018, 68, S371.	1.8	0

#	ARTICLE	IF	CITATIONS
37	Preemptive direct-acting antiviral therapy in naive or NS5A-relapser liver transplant recipients: a single centre experience. <i>Journal of Hepatology</i> , 2018, 68, S371.	1.8	0
38	Role of hepatitis B core-related antigen and antibodies to hepatitis B core antigen level in the natural history of chronic HBV infection. <i>Journal of Hepatology</i> , 2018, 68, S483.	1.8	0
39	First UHPLC-MS/MS method coupled with automated online SPE for quantification both of tacrolimus and everolimus in peripheral blood mononuclear cells and its application on samples from co-treated pediatric patients.. <i>Journal of Mass Spectrometry</i> , 2017, 52, 187-195.	0.7	20
40	Negativization of viremia prior to liver transplant reduces early allograft dysfunction in hepatitis C positive recipients. <i>Liver Transplantation</i> , 2017, 23, 915-924.	1.3	10
41	Impact of direct-acting anti-HCV treatments before liver transplant on virological and clinical outcomes of HCV patients at one year after surgery. <i>Digestive and Liver Disease</i> , 2017, 49, e25-e26.	0.4	0
42	Liver transplantation with an uncommon full right hemiliver graft after hydatid cysts resection: Case report and review of the literature. <i>Transplant Infectious Disease</i> , 2017, 19, e12685.	0.7	1
43	Favorable short-term outcome of hepatitis C virus positive liver graft with bridging fibrosis: A plea for very early viral eradication. <i>Hepatology</i> , 2017, 65, 2116-2118.	3.6	9
44	Donor CYP3A5 genotype influences tacrolimus disposition on the first day after paediatric liver transplantation. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1252-1262.	1.1	19
45	HCV viremic donors with hepatic bridging fibrosis: Are we ready to use their livers in the era of direct-acting antivirals?. <i>American Journal of Transplantation</i> , 2017, 17, 2986-2987.	2.6	7
46	Favourable virological and clinical outcomes at 1 year after liver transplantation in hepatitis C virus-positive patients who received direct-acting antivirals on the waiting list. <i>Journal of Hepatology</i> , 2017, 66, S197.	1.8	0
47	MELD score >19 on day five after liver transplant in hepatitis C virus-positive recipients: impact on 90-day graft loss and analysis of predictors. <i>Journal of Hepatology</i> , 2017, 66, S196-S197.	1.8	0
48	Impact of viral eradication with sofosbuvir-based therapy on the outcome of post-transplant hepatitis C with severe fibrosis. <i>Liver International</i> , 2017, 37, 62-70.	1.9	35
49	NBAS mutations cause acute liver failure: when acetaminophen is not a culprit. <i>Italian Journal of Pediatrics</i> , 2017, 43, 88.	1.0	25
50	Early reduced liver graft survival in hepatitis C recipients identified by two combined genetic markers. <i>Transplant International</i> , 2016, 29, 1070-1084.	0.8	3
51	Peri-hepatic gauze packing for the control of haemorrhage during liver transplantation: A retrospective study. <i>Digestive and Liver Disease</i> , 2016, 48, 414-422.	0.4	14
52	Early Introduction of Subcutaneous Hepatitis B Immunoglobulin Following Liver Transplantation for Hepatitis B Virus Infection. <i>Transplantation</i> , 2016, 100, 1507-1512.	0.5	23
53	Feasibility and efficacy of sofosbuvir-based antiviral therapy before liver transplantation to prevent HCV recurrence: A monocentric experience. <i>Digestive and Liver Disease</i> , 2016, 48, e29.	0.4	0
54	Safety and efficacy of sofosbuvir-based antiviral therapy immediately after liver transplantation: A matched case-control analysis. <i>Digestive and Liver Disease</i> , 2016, 48, e32.	0.4	0

#	ARTICLE	IF	CITATIONS
55	Excellent outcomes of liver transplantation using severely steatotic grafts from brain-dead donors. <i>Liver Transplantation</i> , 2016, 22, 377-378.	1.3	9
56	P183: Liver transplantation for hepatitis B with delta coinfection: a single center experience. <i>Journal of Viral Hepatitis</i> , 2015, 22, 110-111.	1.0	1
57	Antiviral therapy with sofosbuvir plus ribavirin for the treatment of severe HCV recurrence after liver transplantation: preliminary data from a single-centre experience. <i>Digestive and Liver Disease</i> , 2015, 47, e26.	0.4	0
58	Sofosbuvir plus ribavirin in HCV-infected cirrhotic patients awaiting liver transplantation: preliminary data from a single-centre experience. <i>Digestive and Liver Disease</i> , 2015, 47, e55.	0.4	0
59	P0060 : Antiviral therapy with sofosbuvir plus ribavirin in HCV-infected cirrhotic patients awaiting liver transplantation: Preliminary data from a single-centre experience. <i>Journal of Hepatology</i> , 2015, 62, S314-S315.	1.8	0
60	P0063 : Sofosbuvir plus ribavirin for the treatment of severe hcv recurrence after liver transplantation: Preliminary data from a single-centre experience. <i>Journal of Hepatology</i> , 2015, 62, S316.	1.8	0
61	Simultaneous Liver-Kidney Transplantation in Adults: A Single-center Experience Comparing Results With Isolated Liver Transplantation. <i>Transplantation Proceedings</i> , 2015, 47, 2156-2158.	0.3	10
62	Prediction of occult hepatitis B virus infection in liver transplant donors through hepatitis B virus blood markers. <i>Digestive and Liver Disease</i> , 2014, 46, 1020-1024.	0.4	14
63	Excluded segmental duct bile leakage: the case for bilio-enteric anastomosis. <i>Updates in Surgery</i> , 2014, 66, 115-119.	0.9	3
64	Invasive Candida Infections in Low Risk Liver Transplant Patients Given No Antifungal Prophylaxis in the Post-operative Period. <i>Transplantation Proceedings</i> , 2014, 46, 2312-2313.	0.3	11
65	Minimization of Anti-hepatitis B Surface Antigen Immunoglobulins for Prophylaxis of Hepatitis B Viral Recurrence in the First Month After Liver Transplantation: The Meaning of HBsAg Quantitative Level at the Time of Transplant. <i>Transplantation Proceedings</i> , 2014, 46, 2308-2311.	0.3	2
66	A Bayesian methodology to improve prediction of early graft loss after liver transplantation derived from the Liver Match study. <i>Digestive and Liver Disease</i> , 2014, 46, 340-347.	0.4	18
67	Optimizing results of liver transplantation with graft from HBcAb positive donor. <i>Digestive and Liver Disease</i> , 2014, 46, e40.	0.4	2
68	Liver Transplantation for Hepatocellular Carcinoma Within Milan Criteria in Patients With Model For End-Stage Liver Disease Score Below 15: The Impact of the Etiology of Cirrhosis on Long-Term Survival. <i>Transplantation Proceedings</i> , 2013, 45, 2711-2714.	0.3	9
69	Outcomes of Liver Transplantation from Hepatitis B Core Antibody-Positive Donors in Viral Cirrhosis Patients: The Prevailing Negative Effect of Recipient Hepatitis C Virus Infection. <i>Transplantation Proceedings</i> , 2012, 44, 1963-1965.	0.3	5
70	Outcomes of Liver Transplantation in Simultaneously Hepatitis B Surface Antigen and Hepatitis C Virus RNA Positive Recipients: The Deleterious Effect of Donor Hepatitis B Core Antibody Positivity. <i>Transplantation Proceedings</i> , 2012, 44, 1960-1962.	0.3	4
71	<a href="http://www.D-MELD.com">http://www.D-MELD.com</a> , the Italian survival calculator to optimize donor to recipient matching and to identify the unsustainable matches in liver transplantation. <i>Transplant International</i> , 2012, 25, 294-301.	0.8	26
72	Liver transplantation for symptomatic centrohepatic biliary cystadenoma. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, 408-413.	0.7	20

#	ARTICLE	IF	CITATIONS
73	571 TRANSPLANTATION OF THE LIVER FROM A HBCAB POSITIVE DONOR INTO A HCV-RNA POSITIVE RECIPIENT ADVERSELY AFFECTS GRAFT SURVIVAL AND WORSENS THE COURSE OF HCV-RECURRENCE. Journal of Hepatology, 2011, 54, S232-S233.	1.8	2
74	572 THE EFFECT OF D-MELD ON GRAFT SURVIVAL AND COURSE OF HCV RECURRENCE IN HCV-RNA POSITIVE RECIPIENTS AFTER LIVER TRANSPLANTATION. Journal of Hepatology, 2011, 54, S233.	1.8	0
75	Balancing Donor and Recipient Risk Factors in Liver Transplantation: The Value of D-MELD With Particular Reference to HCV Recipients. American Journal of Transplantation, 2011, 11, 2724-2736.	2.6	86
76	Basiliximab Versus Steroids in Double Therapy Immunosuppression in Liver Transplantation: A Prospective Randomized Clinical Trial. Transplantation, 2008, 86, 925-931.	0.5	45
77	Randomized clinical trial of radiofrequency-assisted versus clamp-crushing liver resection. British Journal of Surgery, 2007, 94, 287-291.	0.1	76